Show UniProt / TrEMBL protein name		View in Fasta format (DNA)		View as list

# Vibrio fischeri ES114, ES114

>VFA0046 transporter
MNIAEYSIKNKVISWLFITILTIGGITSFLDLGRLEDPAFTIKDAMVVAT
YPGATSKEVEEELTYPLEKAIRKLPYIDKITSTSSNGMSQIMVSMKMDYG
PDELPQIWDEMRRKINDLKPTLPQGIQSLQIIDDFGDVFGVMMMLTGDDY
NYVELKRYADTLTRELELIDGVGKISIAGDQQEMLFVEISLDRLAALNLD
MNTVAGLLNQQNNVVQAGEVLVTWQQQLQRIRTKWQHYTTVESLGALDHP
WP
>VFA0656 hypothetical protein
MYPDIILLNGTGSSGKTSLAKELQELLSIQYLNFSIDSVLYALPPTDLRR
MIAGDPISRSGYDYGQLTEGYHNCVKGLLEAGCRLIIDNAWINEDEINAL
EKSLSGFNVVRVKVMCRLDVCIARELARGDRAIGLAESEYPLVHNFIKYD
ASVDTSDIQPKDAAVKLLRELKLY
>VFA0308 peptide transport system permease protein SapB
MWIYTIRRFNLFVITLLILTLIGFNILRLDDTSAWAQTPFLSGWLTYLGQ
LLNGNLGVNQYGVKMLNEILRVFPATIELCFFAFFIALIIGTPIGTIAGM
RRGKPLDTLISSIALVGYSMPLFWIALLGLQLGVTPVSGRYSLLYEFDAK
TGFAFIDVLASKSPYRAEMLENIIQHLILPTLVLSIAPMTEVVRLMRSSV
ATVITQNYIKVAHTKGLSKFEIMVKHIIRNALPPIIPKLGVQLSGLFTAA
ILTESIFNWPGIGHWLLDAIINQDFVAIQAGVITVASFILLANILSDLLG
AAVNPLVRKEFYALK
>VFA0307 peptide transport system permease protein SapC
MLSNNVYQEEHIPTQMERFWLSYRANSLAMFGFWCLLLIVIITVTSPWLS
PYDPQWQSDYLLMPPSWSSEGEVIFFLGTDDLGRDILSRLLMGSQLTFGY
AVIVALLSGFVGCVIGIFAGMTKGLLSSTLNHLLDTILSIPSLLLAIIFV
AFLGFGEFNILLAIWLALIPRFVRAVYTAVHNEVEKDYILAARLDGANNF
YLLWNSILPNILVVMVAEMTLAISIAILDITALGFLGLGAQAPSPEWGAM
LGDSVELIYTAPWTVTLPGIVITFTVIIINLVGDGIQRALNAGTE
>VFA0136 hypothetical protein
MSVEYYVDKFRNLNMNSNKGRKSPHKVCMLLSVMDLIQAGYIYKNRFQLD
ATLKERFTHFFNERRHEQDRDTPENPFFHLKSEGFWHLAYQDGIDASLVK
GYSAKAINYAYLDDELFDYLKSIIVVNDLKDALVENLSDLTDLYTQWLID
VGKSEKTAKNYSQAIRGSISNWMIQENILEEPLTKVKSFREFCRLSETAR
SLEKFKKFNANGNHMYSAALNSYQRFLADLSQVDVKADIQEIFEDNKLTQ
TEKTIMVNTRMGQGTFRKQLIEMWKGCSVTGYKNTQMLVASHIKPWREAN
NTERLDKYNGLLLLANLDKAFDLGFISFQNSGKLMISSQLEAPEVLGLRD
DMIFNVHREHKKYLDHHRKILFKGF
>VFA0743 multidrug resistance protein A
MQAAEQKFKQWMRILIVLFLIVTAYLVMADRLTPLTTQSKVQGFVVQISP
EVSGRIVEVNHTNNQLVKKGELLFKIDDEKYLLAVQKAKIALAQAKEQEA
SLVADIEAARSNVKTTQVTANNANREYHRIKRLANSGAVSASGLDSALTK
RDQAAANLMAAKQKVHALEVKLGKGNGQSSAVLSAKNSLKQAELDLEHTQ
VVAQNEGIITNMQLHVGVFANANQPLLTFIPTDSLWVSADYREKATSEMV
KGMRAEVAYDAMPGEVFPLIVESRDYGVASAQQKANGQLSSVEVSNRWVR
DAQRVRVNLTSDEPLSPRLFVGSRATVIIYTSGNSVIDYIGHSLITMISY
LHYIY
>VFA0896 multidrug resistance protein A
MLEGLAVWALFIYLLRMVGMPWNKFTQAFAYIGGGSWLLFVWAGLLNYTP
MDLSGGSVVQSPHIQLRPASTQIKGTVKAIHIEPNQEVKKGQLVYELDDE
LYQIALNKAEVAFEASEVALAVAKQNVKLANQAIIASESDVVVSQKQIEA
KSQDLKYKKLTLQRYVEQNRKVKNTITQSALDEQGTLVSIGEIEVASAIA
QLDKAKLANEKAQLDFDNAKLGVKAKESELASAQESVTQAQWNLDNTKVY
APADGYVTNFILREGQYVGTVPRMQMYTNEKYVLMRVNHQAIRNVKVGRP
AEFSSAVYPGKIFVAEVEGIIEATGEAQANLLGRETNVRQTTGLNVNNKH
HFVRLKLQEDQGYDIPVGSVGLAWVSGEKPIGFMAFLDVIRGIIIRMKSQ
IYFFYSL
>VFA1103 multidrug resistance protein A
MKKSRHFSITFTLFFISSLIGYLIYFAWQYSNNHPSTENAYVRAKIVSIA
PQIKGRIISVEVNDYQKVNKGDLLLKIDPQPYLLAVKRAESAYQLAVQQH
QVADSKVTQAIANLNGVTSNLKETQIEFKRTQALVSRKLSSQQELDIIKN
KLAIAQAKLEEARANVEAAIANRGDDNGVDAAIVQQASAELAQAELDLSY
TDITAPTDGLLGEINVFVGSVVKNSQMLFPLVVKNTYWVRANFKETSLTN
IRMGQTAEVVIDMYPDITWQAKVSELSPASGTSFSLMPPENATGNWVKIK
QRYPVKLILDIPKDSPQLRIGASAEVTINLSDDSRT
>VFA1149 acriflavin resistance plasma membrane protein
MLSRFFIQRPKFALVISIILTLAGAIALAVLPVAEYPKISPPSVSVSAYY
TGASAEVVEQAIADPIETSVNGVENMIYMSSKSANDGSYSLNVTFDVGTD
PDMAQVNVQNRVAQIESKLPQEVRMVGVTVKKRSPDLLMVLNFYSPDGKY
DDQFLINYVNLNIKDQLARVTGISEVGVLGGGEYAMRVWLDPDKMTNLGL
TTSDVHAALAEQNVQVAAGKIGAAPYASAQDVQFNLVTKGRLESVEEFEN
VVLRANNDGSSVYLKDIARVELGKKFYDGNGQFRGKDASIVTLSLQSDAN
ALESGKAVMEMLEKLSATFPEGLAYETSYDTTLFVSESIKGVVKTLIEAI
LLVIAVTYLFLGSARATLIPVVAIPVSLIGTFAVMLMTGFTINTVTLFGL
ILAIGIVVDDAILVIENVDTIMKRDPSLSPRKATLIAMKEVTGPIITSTL
VLLAVFIPVAMLPGITGIMYRQFALTICIAVIISSINALTLSPALCSLVL
KRGGDNTARWFKAFNRGLDKVTDKYGEIAGFFVRKTMILMTFFVIALGAV
TFFAKTTSTAFVPQEDKGILLVNVQLPDSASLSRTEEVSAKVLEIIEQEQ
GVDGVTVANGYAFLTGAAASNGASLFVKLKPWGERNDMDGDNSSFAITNR
INGRAAMELPEAVIFAMGAPAVPGMGAASGFEFVLEDTLGRSRTDLANVM
NQVIQTANQQPEIQYTFSTFRANVPHYYVDIDREKAKQLGVSLGSIFQTL
QGNLGSMYVNDFTMFGKNFRVTMQADGQYRSSMDDLDKFHVRASSGQMVP
LSTLVTYDTVFEPDVAWRYNMYRSAVIQGQPAAGYSSGDAIAAMERVAAE
VLPHGYQYEWTGMAYQEVKAGNQAIYAFALALIFIYLFMVAQYESWSIPL
AIILVVPVATFGSFLALNLTGMPLNLYAQIGLVLLIALAAKNAILIVEFA
KNEREEKEVGLDDASVNGGRLRFRAVNMTSWSFILGILPLVFASGAGYIS
QNSLGVSLIGGLLCVLLVGTLLIPGFYAMVQRRREKLHGGSTKLIPLDDE
>VFA0424 phospholipid-lipopolysaccharide ABC transporter
MTIEKDESTWATFKRLWPHISLYKAGLGVAVVALVINALSDTYMISLLKP
LLDEGFGSADSDFLKKMPFIILAMMFIRGLSGFVSGYCMSWVASNVVMRI
RRQIFNHFMHMPVSYFDQESTGRLLSRITYDSEQVAAATSKALVNIVRES
ASIIGLLGLMFWNSWQLSLVLVVIAPVVAFAISNVSKRFRKISKNMQTAM
GSLTATSEQMLKGHKVVLSYGGQKVESERFDNISNHMRQQNMKMVVAQGL
ANPIIQMIASFALVTVLYLASVDSIKETLTPGTFTVVFSAMFGLLRPLKG
LTSVTSDFQRGMAACQTLFELMDMDKEKDDGTIEKDTVKGDIKVDNVTFT
YPTADGPALRNVSFDLPAGKTIALVGRSGSGKSTIANLFTRFYDVDSGEI
SLDGDKIEDYRLPNLRKHFALVSQNVHLFNDTVANNIAYASEGKFTRLEI
EKAAELAYASDFINKMDDGFDTMIGENGASLSGGQRQRIAIARALLQNAP
VLILDEATSALDTESEKAIQSALDELQKDKTVLVIAHRLSTIEDADQILV
VDEGEVVERGNHAELIAHDGAYAQLHRIQFGD
>VFA0590 daunorubicin resistance transmembrane protein
MISMKTYWRSYFTSPWVMAVTFVLPLLTSLVIWWIFSSNVVRELPIDVVD
LDQSHLSRMMIRDYDATPTLSVKSIQPNKEKANLALTKGDNYGYIIIPHD
FEKNVMLGKSPKITGFYNGQFILIAKQINSALMQTDMTAQAKLSVIKQLS
IKETTWTQAINSAVPIKVQVTPLFNLGSNYNQFLVSAILPAIWQMAVIVG
MLWAMQNESVRTGCNSLREWFDKQDRLSIFNFTLVYFCIAMMLGAVLFYF
LYGVIGFPFNGSITAFILNMSLMSFACISLGIAIGYGTNDIVKAMSISGA
YTAPSFAFLGVTFPVTDMNSLATFWHSILPASHFVRAQNELSNYGDSLVS
AFPNIGVLTLFTLPLLLLSLKLKK
>VFA0537 type I restriction-modification system methylation subunit
MMTQQELEKYLWGAATTLRGTIDAGDYKQYIFPLMFFKRICDVYDEEFEN
ALAESDGDLEYAAFAENHHFQVPKGAHWNDVRETTTNIGLALQNAMRAIE
KANPDTLEGIFGDASWTNKERLSDAMLTNLIEHYSEQTLNLKNVPDDKLG
NAYEYLIKEFADDSGHTAAEFYTNRTVVKLMTMIMAPQPGESVYDPTCGS
GGLLLNCALHLKDEGKEYRTLKLYGQEINLLTSAIARMNMFMHGIEEFDI
VRGNTLSNPGLLENDELKKFNVILANPPYSIKSWDRKAFESDPYGRNVWG
TPPQGCADYAFQQHIQKSLDLGNGRSISLWPHGILFRDAETAMRRKMIEQ
DQVECVIGLGPNLFYNSPMEACLLITKTNKIESKKDKILFINAVKEVRQD
KNIGYLDQVHIDKIFNAYNKFENEDSFAVLVDKQEVLDKKANMAINLYIR
PDSLVSSEEACFATAYQEWQQSSGDLKQSMEKLFKELV
>VFA0463 Lipoprotein releasing system ATP-binding protein LolD
MSNPLLVCQGIRKVYQEGAMETEVLKGVDFQINGSELVAIVGSSGSGKST
LLHILGALDEPTAGTVHFQENELTKLSANKQAKIRNQHIGFVYQFHHLLA
DFSALENVAMPLLIGGVNKKEAAKRATELLEKVGLAHRIEHRPSELSGGE
RQRVAIARALVNKPALVLADEPTGNLDHKTALDIYNLMRELNQESGTAFL
VVTHDNELAAKLDKQLSMQDGRFITETVRSSLAQEMEA
>VFA0306 peptide transport system ATP-binding protein SapD
MPLLDIRHLTIELETPQGMVKAVDRMSLTLNEGEIRGLVGESGSGKSLVA
KAILGITKDNWKISADRMRLGNIDLLALSPKERRRVIGREMAMIFQEPST
CLDPSEQVGNQLKEAIPSKYFTGSWWQRWNWRTKGAIALLHKVGIKDHKH
IMKCYPYELTDGECQKVMIAMAIANKPRILIADEPTDELDAVTQSQIFRL
LSRMNQVNNTTILLISHDLITLTQWVDRITVMYCGQSVESACRKDILEAP
KHPYTNALLRAMPDFSKDGIPHKAKLESLPGTIPPLQHLPIGCRLGPRCP
YAQRKCVQVPERQKVKDHKFSCHFPLNFEEKKNDCAS
>VFA0379 fusaric acid resistance protein fusE
MDLLLILTYTALCIAVFKIFNIPLNKWTVPTAGLGGVVLVGTLVLLMNYN
HPFTQFGGQFYVTTPIVPSVRGKVIEVNVTPNQPVAAGDVLFKIDPIPFQ
AEVIRKQAALSEAEQAALQLESVYKSAQSNTIKATADKDKAYREFKRYEK
GYKKGAFTAQQLDTRKQTYKASEATLESVQAQEQQAKLALESEINGENTT
VARMRAELEQAQFNLDETIVKAPTDGYVTQMALRPGMMAVPIPLRPVMTF
VHTEDQYFVGAFRQNSLQRLRAGFEAEFLFRAIPGRVFKGEVVEVIPAIG
EGQIQASGALLGTNAIRTNGRALVKLKLTDDVSEFHLPAGSNAEISVYSD
SFEHVSIMRKVLIRMKSWQNYLYLDH
>VFA0479 hypothetical protein
MKVKFHLEKDKQPTSDNGMKIIYGSAKRGGYRFRWYCILALVLSPILIMA
YVFFQQYILTLAPGIITTSPVVITAPQDSMVTAINVKEGNQITYGRNVLE
LNDPVLDSDIQFIKTELTNLNKRKSKVQHDLKSYLLAIRNAKDNLESIKK
IKLNYDKFIKEGKVSQVDYANIIGMYNSAQNTLTSADIGYQKALLDSVQV
ELAGGIAQVVRSLNQELVTKLSQKKLLSIHSPYDGNIIEINTVVGQRIKK
GDVLATIASKADPFVIAYLEPKFIEKAKEGSVVTVILPNRERLKGNVSLA
IETTTKLPAQLAKPFEGPKSLLKVKVTLKKKITKEQWVEGMPVQVSF
>VFA0357 acriflavin resistance plasma membrane protein
MDIARYTIAKRTSVWVLIALILFGGYLSYLKLGRFEDPEFVIRQAVINTP
YSGATAQEVSDEVTDIIEGAVQSLQEVKEIKSVSKQGMSEVTVEIKLEFA
GSQAELQQVWDKLRRKVGDAQRMLPPGAGASIVNDDFSDVYALFFAVTGD
GFSDKQLQDYVDDLRRELVLVPGVAKTATLGERQETIFIEMSGERMAKFG
VSAEKVYQVLQKQNMVTIAGSIETDSMRIPVIPSSNVNSFNDLINLQINL
GDNNAVLRLGDIATVTRGYQEPQSMMVRYNGQRAVGFGISNVAGGNVVDM
GDAVKARIAELENQRPLGIELNVISMQSDSVRASVTNFIDNLIAAVVIVF
IVLLLFMGVRSGIIIGFVLLLTVAGTLCIMLIEDIAMQRISLGALIIALG
MLVDNAIVVTDGILVRLQTTPNDSRDDIVSDVVNTTKWPLLGGTVVGICA
FSAIGLSPSDMGEYAGSLFWVILYSMLLSWVFAVTITPMLCYDFLKVKPV
DTQAPVGRVSRWYRQLLTWVIKHRVISLSLLLMVLFTSIYGAKYIPPGFM
PESQRAQFVVDVYLPQGSDIKRTEQTIASIEQDIKQKAGITNITSFVGGG
GLRFMLTYSPEARNPSYGQLLIDIDDYQNIAPLLGELQSELDEKYTDASI
KVWKFMLGRGGGKKIEAGFKGPDSAVLRQLAEQAKTIMLNDPQLIAVQDD
WRQQVPVLRPRYSEEKAQQFGLTTQEINQAIAQTLSGRNVGVYREGNDLI
PIVARSPETERSHQRAIENTEVYSHAVGGFISVSQLVESTDVVWEDAILR
RIDRMPTILVQADPAPGVLTADAFNQVRQKIEAIELPSGYELIWYGEYKA
SKDANEGLVISAPYGFAAMILSVIFMFNALRQPLVIWLTAPLAIIGVTVG
LIIFQTPFEFMAILGFLSLIGMMVKNAIVLVDQADAEIREGKLPYNAIID
ASLSRARPVLLGALTTILGVAPLLIDPFFKSMAVTIMFGLLFATILTLIV
IPLFYAMFFRIKAIEE
>VFA0509 multidrug resistance ABC transporter ATP-binding and permease protein
MFKFFERLTTAFPEQEPNQPPKGLYAFCRHYTKGFEVPLIGMSLLSAVIA
MIEVSLFGFMGQLVDWLSTHDRETFLAQEGQTLLLLGFLIVVIVPILLFI
HSLLTHQTLLGNYPMAIRWQAHRYLLKQSVSFYSDDFAGRIATKVMQTAL
AVRETVMKLLDVLVYVSVYFTSMVVMVGQADWRLMLPMLVWFAAYVAIQF
HFVPKLKAISEQQADARSTMTGRVVDSYTNINTVKLFSHSKRETQYAEEG
MEEFLGTVHKQMRLATGINISVEIINYLLVFSIAAVSITLWLDNVLSVGA
IAIAISLALRVNGMSHWIMWEISSLFENLGTVTDGINTLSKPIEITDKEN
ASELNVSKGTIKFDSVNFNYGENKSVINDLNLEIKPGEKIGLVGRSGAGK
STLVNLLLRFHDVESGSISIDGQDIRDVTQDSLRSQIGMVSQDTSLLHRS
IRDNIKYGRPDATDEDLFAATKQAQAHEFIETLTDSFGSKGYDAQVGERG
VKLSGGQRQRIAISRVLLKDAPLLILDEATSALDSEVEAAIQDSLDELME
GKTVIAIAHRLSTIAAMDRLLVMDKGQVVEQGTHKELVALGGIYAQLWNH
QTGGFISE
>VFA0305 peptide transport system ATP-binding protein SapF
MTALLEVTDLKKDYVFRTGLFRKQVREAVKPVSFSLEAGQTLGFIGANGS
GKSTLARMLAGVVEPTSGIIKVNGEVLDYKDFQTRCKLIRMIFQDPNSSL
NPRIQIGRILEGPLKRNTSMPPEARQQRVKDTLLRVGLLPEHAYFYPQML
ATGQKQRVCLARALILQPSIIVADEALNGLDMAMRSQIINLFLELQQEMA
ISFIYVSQHIGVVKHITDKVMVMHEGEVVEKGPTEEIFSNPQHSITQRLL
ESHFDAPTHDRKQRISAATPKIEC
>VFA0535 type I restriction-modification system methylation subunit
MIEKLTLSQLEQYLSKAAWILKGPVDASDFKVYIFPLLFFKRISDVYDEE
YRVALEESDGDEEYASMPEMHRFEIPTGCHWRDVRETTTSVGITIEDALR
GIEQANQEYLYGIFGDAQWSNKNKLSDELLINLVEHFSQYTLGNQNVEPD
MLGNAYEYLIKHFADLTNKKAGEFYTPRSVVHLLGMILDPHEGETIYDPA
CGTGGMLLECVDHLKDNKEDYRTLKLFGQEKNLTSSSIARMNMFLHGIED
FEILRGDTLRHPAFFEADGLKTFDCVIANPPFSLKDWGSENWANDPYGRN
IAGVPPKGNGDMAWVQHMVKSLNSTGRMTVVLPHGALFRKAAEGKIRKQL
LDQDMLEAVIGLGPNVFYGTQLAACVMVFKQNKPADKKGKVMFIDASDQI
RVGRAQNFLEPNHVQQIYDWYHNYQDVENYVKVASMDELAENDYNLNIPL
YVEKIIEDNLPSVEEAMADLKQAWQASLEAEEKFKSVLKGFLK
>VFA0539 type I restriction-modification system restriction subunit
MGFTELNSVEHYIIHQISGVNLNDAQCKNQVSEPQATYALQWQFKSSEQL
GRDVNEVLVESELVKALIRLNPEIEANPHLADEVIHKLRAILISVNQVGL
VKANEEFFAWMTGEKTMPFGENNRHVPVKLIDLEDLTRNGYVVTNQFRIH
HRETKIPDVVLMINGIPVVVGEAKTPIRPSVSWLDGAHEVHNIYENAVPQ
LFVPNILSFATEGKELFYGAIRCPLEFWAPWRTEEDDNSKGIGQVSKALG
LTEIGKELIDLLSPVRLLDIMRNFSLFTTNKKKQRIKVIPRFQQYEGANK
IVERVIEGKIKKGLIWHFQGSGKSLLMVFAAQKLRRTAQLKSPTVIVLVD
RTDLDTQISGTFNAADVANVESTDSIKELQRMLERDTRKIIISMIHKFRD
AKPNMNTRENIIVLVDEAHRTQEGDLGRQMRAALPNAFLFGLTGTPVNKA
DKNTFWAFGAEEDKGGYMSRYTFHDSIRDEATLPLHFEPRLVDVHVDKEA
LDKAFKDFKESAALSDEEADALNQKSAKMSAFLKSPERVEKIVEDIAIHF
MDKVEPHGFKAMVVTPDREACVQYKEELDKHFPESASKVVISTSANDDFE
FKQKWGVDKSQQEKLVDEFNDEKSDLKFLVVTAKLLTGFDAPICQTMYLD
KSIKDHTLLQAICRTNRLYPNKTFGCIVDYFGVFDDAAKALEFDEESVQQ
VISNLSELRSKLPQAMQDTLAHFIGVDRSLEGFEGLEAAQNAIGDNDKKD
AFALDFKYLAKLWESLSPDSVLDEYNEDYKWLAQVYESVKPASDNIGKLL
WLALGAQTTQLIHDNVHVGDVHNLEEFVLDADVIENIFNNPDPRKIKQLE
KELAKRFKDRGDLPVFKSLSERLEELRDKAEKGLIASIDFVKELCKIAKE
TVQAEKDLDDELQEKTPQAALTDLFLELKDDQTPAVVERIVTDIDAIVRI
VRFPGWQTTTGGEREVQKSLRKALLKYKLHTDQTLFDRAYGYIKEYY
>VFA0916 Na(+) driven multidrug efflux pump
MTTFHADSSITRTFWRYAIPSIAAMVVSGLYQIIDGIFVGHYIGFEGLAG
INMAWPAICILGAIGVMVGMGTGSVMSIYRGENKLEKTKVALTTGFWLLA
ILSIIAISCIVLLAKDILLAQGAEGQNFAYAMDYINVLMFGGFFTACATA
LPMLVRNDESPNVATFLLVIGALINIVLDYVFIGVMGLGLSGAALATLMA
QACVTVLGIGYFFTQRSSIQITLQEVLFSWNKAKQSLSLGASALVMYLYG
SFVVAMHNALMMYYGSATTVGAYAIVGYLFMLYYLLAQGIAEGAQPPISY
YFGARENKKVYQIFKIALKWVIITGIGWVTILNISPELTTALFTNGDKAL
IAETIVGIRYHLFAMFLDGMIVLITIYFLSVNEGKKAMVISISNIVIQLP
FLLILPKWFGIDGVWLAMPVSNIALIICIAPMVWNHLKTQKIIKPLPLTS
TSVMSH
>VFA0112 export ABC transporter permease protein
MKSMNRMKAIMMKEIRQLSRDKLTFGMVIMIPLIQLLLFGYAINTDIRDI
PVAVVDQSESTLGRLITESVKVTQVVNIKQYYPTVEEAEKAIQQGVVRAA
LVLPKDITQRVMQKRELGQWIVDGSDTMISAAILSLQTMPLADLDFDVRN
TAKAKTFEVTLFYNPSRRSAVNIVPGLLGVILTMTMVLFTSSAIVRERER
GNLELLITTPIRSFELMVAKIIPYIFVGLIQVLIILGLGYAIFDVPINGS
LSQILFGTLLFISASLTLGLVISTIAKTQLQAMQMTIFILLPSILLSGFM
FPYEGMPVIAQWIAEVLPATHFMRLIRGIVLRGADLMDLWRDTIWMIVFT
LIGLFVASKRFKKSLD
>VFA0907 acriflavin resistance plasma membrane protein
MLSKFFIHRPKFALVISLVMTLMGLIALKVLPIAEYPAISPTVIIVNTVY
PGANADVVKKTVAQPLESKINGVEDMIYMSSNIGNDGSYSLRVYFRIGAD
GDMAQVRVNNLVSQATSTLPPEVKQIGVTVRKKSSDILGVVTLSSPNKTY
DSIYLSNYADLNLVERLKRLEGMSDITLLGKKSYSMRIWLNPNKMSTLNL
TAKDVISAVKSQNIQVAAGKIGGMPAPDQQQNQYVLQTKGRLTSTDEFAN
IVIRANKDGSIIRLSDVARLELGAQGYEADGQLNNQPAAVMALYQLPTAN
ALDAMSKVKAAMKEYSKTFPDDLEYNIAYDSTEYVEASIDEVYETLIIAA
LLVAIVVYVFLQNLRATAIPIIAIPVSIIATFAVMSLMGMTINTISLFGL
ILAIGIVVDDAIIVVENVERIIHEKHMKPIPATIEAMKEVTGPVLATTLI
LLAVFVPVALLPGISGKMFNQFAVTICVSVLISAINALTLSPALCGLILT
DKHSEPIAPLRAFNRGFDAVTKKYQFLVGFMSQRLLVSSVIYIALIGVLG
YTFMTIPTAFVPNEDKGAFMVEMRLPDSASLQRTIPILQDYTRDLLEMDG
VEDVVSVSGFSLINMSAIPNAGMLIIKLNNWDDRKDPALHQKALMNKVRQ
MLNTIPNANALVFATPAIRGMGSVDGFNFVLEDNLGRSPQELAQTTQNFV
AKINQLPEVARAFSIFRANVPQRFIDVDRDKAISMGIPLNDIFQTLQSQL
GGAYISDFNIYGRSFQVKVQAEQEYRDSTDDINNLYVRNNTGKMVSLGTL
VKIKPIFGPDSLMNYNLFGSATINGVPASGYSSGDVVKAIEKLAENELPK
GYSFEWSGMTYQELEAGNAAPVAFALSLLFTYLFLVAQYESWSIPTAVMM
AVPIAILGAMATLFALGQPFDLYVQIGIVILIGMSAKVAILIVEFAKVLR
EEKGYSIIEAAKEAARLRFRAVQMTAFAFIWGVFPLVIASGAGAESRHSL
GFAVFGGMILSTLIGTIFTPVFFVTMQSLRERFNPKK
>VFA0467 hypothetical permease
MDVKFHLEKKNKPTSDNGMKVLYGMEKRGAYRFRWYLILAIILSPIFFMI
YTFAKQHLFTVAPGIITTGPVIITASQNGTVKLIDVKDSEFVLEDQLLME
LDAPILEQEIEFIENELEQLYQEQTQKITEDFGPYISAIGAAKLNLKKIT
KIKVNYDQYAKEGKVSQVDYAAIVGIYNTAQNNLTNAYIALNQAEIAQKQ
RLLAGGVAQVTRELNQALTTKKNQLDALSIRAPYMGLVIDINALKGQQIS
IGDPLVTVSPDVAPYVISYLDPKHIEKAKLGALVTVKLPNGKKVEARVSS
AIGLTSKLPIQLAKPFEGAKALLKVKITFLGGVLEKEWVEGMPVEVYF
>VFA0111 daunorubicin resistance ATP-binding protein DrrA
MTELAIQAKEVVKKFGDFTAIDGINLSVPKGSIYGFLGPNGCGKSTTIRT
LTGLLSPTSGTVDVLGLCIPKESEALRLKIGYMTQKFSLYDDLSVEENLE
FIGQIFGMEKQLLNARVSEQLATYGLDQLRKQRVSGMSGGQKQRLSLAAA
TMHNPELLFLDEPTSAVDPENRREFWEQLFDLSDKGTTILVTTHYMDEAE
RCHRLAIMESGIIRADGEPEELMANMGVNIVEVKANNLRALKAKLIACDE
VRSAAQLGIRLRVLIHQHIDDPILWLRTNFSELKDAEMNIARPSLEDVFV
TVTGKGRQ
>VFA0737 ABC transporter ATP-binding protein
MISFKGIEKTYQLGLQRVEALKQVDGFIIKGSMVALCGPSGSGKSTLLNI
LGLLDMDYQGEIKMDGEFYPKDPIEAAKLRRHQLGFVFQRFNLVPVMTAL
ENVAYPLVLNGYSSKEQRILATEMLEKVGLGDVIHHRPDNLSGGQQQRVA
IARALVHKPSLVIADEPTASLDSQTAETVIDIMKALGKEIGTTFIVATHD
YRMAQHCDTCINLLDGTISKEAVSCAS
>VFA1165 type I protein secretion ATP-binding protein
MKKWKAFNMKDSLLHSLCYVSRYYGQINSPEALINGLPLQDGKLTPFLFS
RAAERAGLVAKENQGELLSIPQLILPVVLLLKGGESCVLIGFDAERKEAE
IITLSSDMLPISISVEDLEAQYIGRYILLKKQFRYDDRSPEILKKREGHW
FWSTLFESKHIYRDVFIASILINIFAIATPMFTRLVYDKVVPNLAFESLW
VLASGIFVVFVFDFILKYLRGYFIDVAGKKSDVLISSKLFQKVLGIRMEA
KPASVGAFARHLQEFESIRDFFTSATIASLIDLPFALLFLFIIYLIAGPI
VLVPVVGITLLLIHAAIIQGPLKKTIEEGSRLSSQKYANLIESLVGLETL
KIFNAQSQYQYRWEEAVTHISNWSIKSRRITDSIQNMAGFVQQAVNIGMI
IVGVYLISNGDLTMGGLIASTMLSGKAIGPLVQISLLSSRYNQAKSSMTI
IEELMAMPDEQEEEKRYIHRPILQGKIELDKVSFNYPEAEVAAVRDISLT
INPGEKVAIIGRIGSGKTTLERLIMGLYKPTAGSVRIDDTDISQLHHVDV
RRNIGCVPQDITLFYGSIRENIVLGRELSDDAEVMDAANRAGVTAFTQQD
PAGLERQVGEGGLLLSGGQRQSVAIARALIGRPPVLLLDEPTSCMDNRTE
MLFKNQLSHLKPAETLVLITHKTSMLDVVDRLIVMEKGHIITDGPKEQVL
NELKTGKVRAVS
>VFA0912 ABC transporter ATP-binding protein
MELIMVLLLNNHNQFNQLRHRMNPIITVSSVSKHYPDSNQAQQALDNISF
TLSSGQVLGLLGHNGAGKSTLINALLGAHRFSGNITINGLEPIENHAELM
KHLAYISDVNVLPEWMTIKQILKYTSGVHPYFDINKALSLITKTNIKLGS
KIGSLSKGMKVQIHLALVIATNVKVLILDEPTLGLDLLYRDNFYNDLMAW
FNQGERCLIIASHEVNEIEKLLTDVLILKQGKCVKLDNMNNIPKGTLADL
FITLQKEVI
>VFA0047 acriflavin resistance plasma membrane protein
MIIHGRDTGNLIRLKDVATITRGLQEKPGNIIRFNGKNALNIGLSFASGV
NVVEVGQRVQEELTYLESIKPAGLELSYFYNQAQEVDTSVRDFIISLAEA
VAIVIVVLLFAMGMRSGLIIGVVLLLTVFGTFILMSYNNIDLHRISLGAL
IIALGMLVDNAIVVVEGILVGLKKGRTKVQAAADIVKQTQWPLLGATVIA
IAAFAPIGLSEDATGEFMGDLYWVLCYSLFLSWVTAITITPFLADLLLKE
EDKNTGVEEDAYKGFLFTAFGSSLKLALRFRWLTVASLVGLLVVAVMAFG
NVKQQFFPASNTPMFYVDMWMPEGTDIRETIKQSEAVESYINKQDNIEFV
SASIGQGMQRFALTYQPEKSYEAYAQFQIRTTDRESMFSLLENLTNSLDQ
RFDKPTFQFKMMEFGPSPASKIEVRISGPDPQILRNLATNVEDIILTDPG
SRNIRHDWRERTKELTPIFNESKARRLGISKEDLSNTLQMAFGGSTLGML
RDGTHTLPIVTRLPESERVDFESLQNVKIWSPSLQTYIPVDQVIDGVNLD
WSEPLIQRRDRKRTITVMADHDLLSDDTPASLLARIQPKVMELPLPEGYE
ITWGGEYESSKDAQESLFGSLPMGYLFMFIITMLLFNSVKKPLKVIWFTV
PLSIIGVAFGLLGTNMPFSFTAFLGLLSLSGMILKNGIVLLDQINLELAS
GKDPYLAIVDSAISRVRPVSMAALTTILGLIPLLFDAFFSSMAITIMAGL
GFATVLTLIVVPVMFAILFKIKPAAQTI
>VFA0589 integral membrane protein
MSLFLLIQKEAKAIFSNTTIVLAMIGGVLFYAFLYPLPYQHQSPEEQKIS
VVDLDKSELSRKFARMVNTSQQVNVVEQANSIEQAKSQFLNNEITGFLVI
PSEFSKKLQLGEAPTVGYAGDASYFLIYGTIVEGLMTAGGTISAEYRIAH
LAIDGTPMNAAIHSFRPFQSNYIPVFNHYMGYVQYVVPAVFVLILQQTLL
MAVGVRQKQSSANENTVTHLIVRFGIFLFTELLLACLYFGYFFDFYSISR
FGTPLEILVLLVPFISSVILLGLFLGKVLPTSESILLLVLFSSMPIVFSA
GFIWPAEMVPSIITDIMHLLPSGFAINGFLKLNQQGAGLGGVLTNLSGLY
ARCILYAFLFFITRNKNNLKGDTE
>VFA0538 type I restriction-modification system specificity subunit
MLDMEAVKNFSIDKSDWKKVKFGDVVFEPKESVKDPVSEGIEHVVGLEHI
ESGDMYLRRSASIEGSTTFTKKFVKGDVLFGRRRAYLKKAAKAKFSGICS
GDITVMRARDELLLPDLVPFIVNNEKFFDYAITHSAGGLSPRVKFKDLAN
FEFFIPSKTDQKKLLSLLEGLDESLQNELILKQKLVSNLEAQIEHQIHGE
HLDGKTINQVIKSLSSKKKIIKLKGLGEIIKGKGIAKSEVVESGIPCVRY
GELYTKHHRMIRKFHSYISLKSSEKSVKLRVNDVLFAGSGETISEIGKSA
AFTESVDAYAGSDILIFRPKDMDGSYLGYLMNSLLVRHQLNKLGTGATVM
HVYGSDIQKIVVPYRDKDEQVQIANCLEEIASNIRLLDRKIHKTKELLAV
LLSKVF